Remark: This recommendation does not apply to non life-threatening bleeding. No data are available comparing the efficacy of 4-factor PCC and coagulation factor Xa (recombinant), inactivated-zhzo. The guideline panel offers no recommendation for 1 approach over the other. Recommendation 18b. For patients with life-threatening bleed- ing during oral direct Xa inhibitor treatment of VTE, the ASH guideline panel suggests using coagulation factor Xa (recombi- nant), inactivated-zhzo in addition to cessation of oral direct Xa inhibitor rather than no coagulation factor Xa (recombinant), inactivated-zhzo (conditional recommendation based on very low certainty in the evidence about effects ). Remark: This recommendation does not apply to non life-threatening bleeding. No data are available comparing the efficacy of 4-factor PCC and coagulation factor Xa (recombinant), inactivated-zhzo. The guide- line panel offers no recommendation for 1 approach over the other. Recommendation 19. For patients with life-threatening bleed- ing during dabigatran treatment of VTE, the ASH guideline panel suggests using idarucizumab in addition to cessation of dabigatran rather than no idarucizumab (conditional recommendation based on very low certainty in the evidence about effects ). Remark: This recommendation does not apply to non life-threatening bleeding. Recommendation 20. For patients with life-threatening bleed- ing during LMWH or UFH treatment of VTE, the ASH guideline panel suggests using protamine in addition to cessation of LMWH or UFH rather than no protamine (conditional recommendation based on very low certainty in the evidence about effects ). Remark: This recommendation does not apply to non life- threatening bleeding. Anticoagulant resumption following bleeding Recommendation 21. For patients receiving anticoagulation therapy for VTE who survive an episode of major bleeding, the ASH guideline panel suggests resumption of oral anticoagula- tion therapy within 90 days rather than discontinuation of oral anticoagulation therapy (conditional recommendation based on very low certainty in the evidence about effects ). 